NLCP › analyze
NLCP · Analyze
A portfolio-specific passage was removed from the public build.
1. What this updates
Baseline: analyze-2026-08-04.md — HOLD 5.0, FV $14.00–18.00 (weighted $15.80), entry $12.50–13.50, trim $21.00.
The August file landed two days before the Q2 print and flagged itself provisional. This pass tests what the print and six subsequent weeks did to it.
Event list since 2026-08-04 — the only forces this pass carries
| Date | Event | Touches |
|---|---|---|
| Aug 5–6 | Q2 2026 print. Revenue $12.087M (-1.8% QoQ, -6.5% YoY, 6th consecutive decline). AFFO $10.3M / $0.49/sh (+2.1% QoQ). FFO $0.47/sh. Dividend held $0.43. Payout 88% — improved from 90%. | T1, T2, T3, St1 |
| Aug 5 | Revolver amended: maturity May 2027 → May 2029; rate Prime+1.0% → Prime (6.25% floor); $90M commitment preserved. | T6, St3 |
| Aug 5 | Kentucky dispensary acquisition — $0.6M close + $1.6M capex commitment = $2.1M, leased to C3 Industries. First deal in 18 months. | T4 |
| ~Aug 12 | HG Vora 13G/A: position cut 1,615,000 → 650,000 sh (7.8% → 3.1%). Still passive. ~60% reduction of the largest identified institutional bid. | St6 |
| Aug 18 | DEA final post-hearing brief argues FOR Schedule III (broader rescheduling). ALJ recommendation pending. | R1 |
| Aug 21–26 | ALJ orders hearing-transcript corrections; final version public. Recommendation not yet issued. | R1 |
| Sep 15 | Q3 2026 dividend declared $0.43 — 10th consecutive quarter frozen. Payable Oct 15. | T3, St1 |
| — | Vacants unchanged: Fitchburg / Sparks / Pottsville still dark, 13+ months, no signed re-lease, no impairment. | St2 |
| — | Cannabist still current on Q2 rent; Vireo lease-assumption path unchanged (no closing announcement). | St4 |
| — | Uplist: management now framed as "actively evaluating NYSE/Nasdaq, no decision" — softer than baseline's "engaging exchanges." No application filed. | J3 |
| — | Price $15.75 → $15.19 (-3.6% over six weeks; range $15.07–$16.10). | P1 |
Nothing here overturns the shape of the August file. Forces net modestly in the dividend-safety and refinancing direction; the institutional bid thinned; the rent roll deteriorated another quarter but the AFFO number stopped deteriorating. The verdict moves one notch — not more.
2. The delta ledger — full table
🔄 SUPERSEDED — the one row that carries real information
| # | Baseline claim | Aug 2026 fact | Force |
|---|---|---|---|
| St6 | "HG Vora at 1,615,000 shares = 7.8% (13G/A 5/15/26). Filed passive — no 13D, no activist campaign… HG Vora is activist-capable; a 13G→13D conversion is worth monitoring." | 13G/A ~Aug 12 2026: 650,000 sh = 3.1%. Passive still. ~965K shares sold in the quarter — ~60% of the position. | ▼ material. The single largest identified institutional bid did not convert to activism; it partially exited. |
Why this matters more than it looks. The August file described HG Vora as essentially the entire institutional footprint (8% Yahoo → 7.8% HG Vora alone). Cutting to 3.1% removes both the "activist-capable" upside optionality (the fund walked before pressing on uplisting) and much of the price support on a name that already trades ~81K shares/day. It also weakens the counter-argument for a 508bp cap-rate gap versus IIPR being "just" a liquidity/access discount — because part of that access just left. Direction: -.
📉 DRIFTED / REFRESHED — the operating series stopped confirming the deterioration story
| # | Baseline claim | Aug 2026 fact | Status | Force |
|---|---|---|---|---|
| T1 | "Revenue has fallen five consecutive quarters (−6.8% YoY)." | Q2'26 revenue $12.087M — 6th consecutive decline, -1.8% QoQ, -6.5% YoY. | 🔁 REFRESHED | ▼ small |
| T2 | "AFFO/share −12.7% off its Q2'25 peak." | Q2'26 AFFO/sh $0.49 = -10.9% off $0.55 peak, and +2.1% QoQ off Q1's $0.48 trough. | 🔁 REFRESHED | ▲ small — sequential improvement is the first in five quarters |
| T3 | "The payout has walked from 79% to 90% — the ceiling of management's own band — in four quarters." | Q2 payout 88%. Stepped back inside the band. TTM 89%. | 📉 DRIFTED IN FAVOR | ▲ moderate — the payout-break argument was the central bear case row |
| T4 | "$1.49M in FY25, $0 in Q1'26… growth is now capped at ~$4.2M/yr of retained AFFO." | Kentucky dispensary $2.1M (Aug '26). First deal in 18 months. Direction of travel changed; magnitude versus $107M liquidity homeopathic. | 🔁 REFRESHED | ▲ small — stall paused, engine not restarted |
| T5 | "Buybacks ceased. Diluted count is now rising as stock comp resumes unoffset." | Q2 share count 20,580,766 — +30K shares QoQ (0.15%). No Q2 repurchases. $8.2M authorization still unused. | ✅ CARRIED | flat |
| T6 | "Debt $7.6M = 1.8% of assets… no maturity until May 2027." | Revolver extended to May 2029, rate cut to Prime (6.25% floor) from Prime+1.0%. Balance still $7.6M. | 🔁 REFRESHED | ▲ moderate — the "no forced action" leg of the thesis lengthened by two years and got cheaper |
| St1 | "AFFO payout 90% Q1'26." | Q2 payout 88%. TTM 89%. | 🔁 REFRESHED | ▲ small |
| St2 | "3 vacant cultivation properties: $71.1M invested / $62.9M net book / 12+ months, zero rent, no impairment taken." | Same three buildings. 13+ months, no signed re-lease, no impairment. Q2 "Property Carrying Costs" line persists. | 🔁 REFRESHED | ▼ small — the twelve-month failure-to-clear finding sharpens with a fourteenth month |
| St3 | "Cash $24.8M · liquidity $107.2M · no maturity until May 2027." | Cash $25.8M Q2. Revolver commitment $90M preserved to May 2029. Liquidity range functionally unchanged; maturity wall +2 years, borrowing cost -100bp. | 🔁 REFRESHED | ▲ moderate |
| St4 | "Cannabist: CCAA Mar '26 + Ch.15 May '26 — still paying full rent. Deposits $481.6K ≈ 1 month." | Q2 Cannabist rent collected in full. Vireo asset-purchase agreement (IL, MA disclosed Jul '26) — no closing announcement. Deposit level unchanged. | ✅ CARRIED | flat — the risk did not fire, but the resolution has not closed either |
| R1 | "DEA grants broader Sched III — ~45% odds ever. Administrator Cole a known skeptic." | DEA argued FOR Sched III in Aug 18 post-hearing brief. ALJ recommendation pending, NPRM expected before YE '26, final rule possibly '27. Cole has not publicly reversed posture. | 📉 DRIFTED IN FAVOR | ▲ small — nudge to ~50%. The base-case-positive leg of the two-sided thesis strengthens without the base-case-negative leg weakening. |
✅ CARRIED without change — structure held
| # | Claim | Why it did not move |
|---|---|---|
| S1 | Regulatory arbitrage protects the industry, not NLCP; site-specific license switching costs are the only genuine moat. | No portfolio change, no franchise event, no ruling that touches license portability. |
| S2 | 90.8% cultivation / 9.2% dispensary by invested capital; capital is in the wrong half of its own moat. | Q2 portfolio: 34 properties, 15 cultivation / 19 dispensaries, 31 leased. Concentration unchanged. Kentucky dispensary too small to move the split. |
| S3 | Top 3 tenants 52.4% of ABR; Top 5 = 70%; Curaleaf Mt. Dora = 17.5% of capital. | Q2 disclosures reiterate the same concentration figures. |
| S4 | Both macro paths damage the business — legalization destroys reinvestment economics; prohibition destroys the rent roll. "Melting ice cube that pays you while it melts." | The shape of the trade-off is intact. DEA Aug-18 posture shifts the odds mix between the two paths, not the trade-off itself. |
| S5 | WALT 11.9y; 0.8% of leases expire through 2029; 57.5% after 2035. | Q2 investor deck reiterates the same schedule. |
| St7 | Weinstein board departure (Jul '26); founder-CEO-turned-director departed three weeks pre-print, sold below book. | Historical event; no new information. Board still 6. |
⏳ UNTESTED — flagged and named
| # | Claim | Why untested |
|---|---|---|
| St5 | Calypso (7.8% ABR) — deposit fully drained Feb 2025, no disclosure of replenishment. | Q2 10-Q reviewed; no line item observed. Silence is not confirmation. This is now the second consecutive pass this question has been deferred. |
| — | "Yahoo's 18.1% insider vs a 5.2% Section 16 roster sum" | Same reconciliation gap, unchanged. |
| — | "No independent appraisal exists for the three vacant properties." | Still unresolved. The $95/SF blended mark is still a reasoned range, not a comp. IIPR/Vireo NY grow (seller-financed 55% at 15%) remains the only 2026 comp and remains distorted. |
| — | Impairment test on the three vacants — undiscounted-cash-flow standard. | GAAP standard unchanged; no impairment recorded through Q2; the softness in $62.9M of net book is unchanged. |
🆕 NEW — findings with no baseline counterpart
| # | Finding | Direction |
|---|---|---|
| N1 | Revolver extended May 2027 → May 2029, rate Prime+1.0% → Prime (floor 6.25%). The refinancing wall the baseline named is pushed out; if drawn, the cost dropped ~100bp. Baseline liquidity math ($107M) still holds, and the maturity leg strengthened. | ▲ moderate |
| N2 | Kentucky dispensary — $2.1M, C3 Industries as tenant. The "$0 in Q1'26" line the baseline led with is no longer true. Deployment cadence at $2.1M/qtr is still trivial vs $23.9M of cash + $82.4M of collateralized capacity, and does not touch the vacants. But the direction is not zero anymore. | ▲ small |
| N3 | HG Vora ~60% exit. See SUPERSEDED St6. | ▼ material |
| N4 | DEA argues for Schedule III in post-hearing brief. Slightly raises broader-rescheduling odds. Administrator Cole (decision-maker) unchanged publicly; DC Circuit petitions unchanged. | ▲ small |
| N5 | Q2 AFFO/sh sequentially up. First non-decline sequential quarter since Q2'25. Not a return to growth — a single tick — but the baseline's "trend broken" framing was ready to add a sixth data point that instead did not arrive. | ▲ small |
3. How the close calls were decided
Was the operating series close-call the right way to read it? Q2 revenue -1.8% QoQ but AFFO/sh +2.1% QoQ. Two independent forces pull opposite directions in the same print. Resolution: G&A stepped up quarter-over-quarter (from $1.421M Q2'25 to $1.912M Q2'26), so the AFFO improvement came from the offset lines (interest income, straight-line rent, no new Property Carrying Costs surprise) rather than operations. The right characterization is "the deterioration paused, it did not reverse" — a REFRESHED-in-favor T2/T3 combined with a REFRESHED-against T1 — and this is exactly why the two rows do not collapse into one status. Same as CARRIED, but named.
Was HG Vora's cut SUPERSEDED or NEW? SUPERSEDED, because St6 named the specific hypothesis — passive-to-active conversion — that has now been refuted in the opposite direction. Recording it as NEW would silently drop the baseline's own bet.
Did the revolver amendment justify moving T6 more than one notch? No. The maturity extension is real and material (it removes a 2027 refinancing question from the risk stack), but T6 was already CARRIED-flat at "no leverage, no maturity for years." Two years further and 100bp cheaper is a REFRESHED-in-favor, not a paradigm shift. The claim it modifies was already at low intensity.
Did the Kentucky acquisition retract T4? No. T4 said the engine has stalled at $4.2M/yr of retained AFFO. A single $2.1M dispensary — announced concurrent with an earnings print — does not restart an acquisition machine; it is one quarter's crumb from a company sitting on $23.9M cash and $82.4M of undrawn revolver capacity. The vacants are still what the capital is for and still where nothing is happening. T4 REFRESHES; it does not retract.
Does the DEA Aug-18 brief drive a status change on R1? Small. The DEA arguing for Schedule III in a post-hearing brief is materially different from the market's prior read that Cole opposed it, and it moves the ~45% odds toward ~50%. But the decision is Cole's, not the ALJ's. ALJ recommendations are not binding; the DEA Administrator can accept, reject, or modify. A brief argues; a rule promulgates. DRIFTED IN FAVOR, not SUPERSEDED.
Where the forces balance overall. Two moderate ▲ (revolver, payout receded), two small ▲ (Kentucky, DEA), one material ▼ (HG Vora), one small ▼ (revenue 6th consecutive quarter). The material negative is roughly matched by the two moderate positives, and both smalls net out. Baseline stands with a modest upward tilt.
4. Thesis persistence and conviction delta
Persistence: 5 of 5 Structural rows CARRIED. 4 of 6 Trend rows REFRESHED (three in favor, one against). 4 of 7 State rows CARRIED or REFRESHED-in-favor; 1 SUPERSEDED against; 1 UNTESTED. Structural persistence 100%; trend persistence 100% (nothing broken, direction mixed). This is the classic profile of a valued-fairly annuity: the shape does not move, the increments do.
Conviction 5.0 → 5.5. Driven by, in order: 1. T6/St3 (revolver extension +2y at −100bp) — the "cannot be forced to do anything" leg materially strengthened. 2. T3/St1 (payout receded 90% → 88%) — the central bear-case row moved away from the break line. 3. Offset by St6 (HG Vora ~60% exit) — the largest institutional-support argument weakened. 4. Offset by T1 (6th consecutive revenue decline) — the top line still has not stabilized.
Half-point up, not a full point, because the mixed profile is real. The verdict remains HOLD.
5. Updated verdict — HOLD. Do not add. Conviction 5.5/10
| Verdict | HOLD — dividend more clearly safe than in August; thesis still deteriorating at the top line; no margin of safety at $15.19 |
| Conviction | 5.5 / 10 (+0.5) |
| Fair value | $14.50 – $18.00, central $16.00 – $16.75, scenario-weighted ~$16.10 |
| Price | $15.19 — ~5.6% below weighted fair value |
| Entry zone | $12.50 – $13.50 — unchanged |
| Trim | $21.00 — see the trim-write-out guard below; do not convert to a bare multiple until the site can accept an AFFO denominator |
| Yield at $15.19 | 11.32% (was 10.92% at $15.75) |
| AFFO multiple | 7.60x on TTM $2.00 |
Valuation re-derive
AFFO/sh TTM = Q3'25 $0.52 + Q4'25 $0.51 + Q1'26 $0.48 + Q2'26 $0.49 = $2.00. Essentially unchanged from baseline's $2.09 FY25 → $2.00 TTM. Payout on $1.72 = 86% on TTM basis.
NAV (primary anchor, 40% weight): Cap $46.0M leased NOI at 14.5% + three vacants at blended $95/SF ≈ $23M mark → $16.58. Unchanged since the two moving inputs (leased NOI, cap-rate build) did not move. Range $16.00–$17.25.
AFFO multiple (30% weight): 7.60x is 60bp below IIPR's ~8x — the discount widened marginally as NLCP drifted while IIPR held. At 8.5x on TTM $2.00 → $17.00.
DDM zero-growth (20% weight): $1.72 ÷ 13.5% required = $12.74. Central range $12.30–$15.60 unchanged. Backward solve: at $15.19 with D = $1.72 and required return 14.2%, the market implies g = 2.87% — modestly less demanding than the August 3.28% (because the price fell). Still not credible on flat AFFO/sh.
DYT (5%): 1-year band $14.66, 2-year $15.45. Same conclusion — does not fire.
Bogle (5%, context): Base case ~11.3% coupon + 0% growth = ~11.3% expected total return.
Scenario-weighted fair value
| Scenario | p | FV | Change from baseline |
|---|---|---|---|
| Bear | 25% (was 30%) | $11.00 | Bear weight ↓ because payout receded 200bp and revolver extension removed a 2027 forced-action risk. Bear FV ↑ slightly because dividend cushion is 12% now, not 10%. |
| Base | 55% (was 50%) | $16.60 | Base weight ↑ because the trend direction stopped being purely one-sided. |
| Bull | 20% (unchanged) | $22.00 | Adult-use leg odds unchanged; DEA Aug-18 brief moves it modestly but re-lease correlation cap holds. |
| ~$16.10 | Weighted, +$0.30 vs baseline's $15.80 |
A portfolio-specific passage was removed from the public build.
Actions
| Self (14sh, $220) | Hold. Same fragmentation flag as August — half an average position; forward to /rebalance, not to this report. |
| Beta (120sh, $1,890) | Hold. Do not add. Defensible size for a ~12-year annuity + call option. |
| Entry | $12.50 – $13.50 unchanged. |
| Trim | $21.00 — the site-derives-trim-from-GAAP-EPS trap the baseline documented is unchanged. NLCP GAAP EPS (ttm) $1.18 vs AFFO/sh $2.00 (70% higher). A 10.5x multiple-trim renders at $12.39 — below current price. Do not convert until site accepts explicit AFFO denominator. Keep the dollar figure with a written-out multiple beside it. |
Break triggers (thesis void, not merely stale)
- AFFO payout >100% for two consecutive quarters
- Any base dividend cut
- A second tenant default >5% of ABR (Calypso, Cresco, Cannabist next in line)
- Impairment taken on the vacant portfolio
- D.C. Circuit vacating the April 2026 Sched III order (~20% tail; reverses 280E relief on 50–55% of ABR)
- MA Question 8 passes (Nov 3, 2026) → Fitchburg loses even its residual bid pool
Upgrade conditions (would move conviction toward 7)
- A signed re-lease on any of Fitchburg / Sparks / Pottsville
- An uplisting application filed (not "evaluating")
- HG Vora conversion 13G→13D
- Two consecutive quarters of stable-to-rising revenue
- Broader Schedule III finalized (not just briefed)
6. What this pass did NOT test — named for the next run
- Calypso deposit replenishment — deferred by two consecutive passes now. Q3 print (Nov) is the third opportunity; if unresolved then, this is a disclosure-avoidance signal to the risk column, not a data gap.
- Vacant property impairment — the undiscounted-cash-flow standard makes this legal; the twelve-months-thirteen-months-fourteen-months failure to clear makes it thin. No independent appraisal has appeared in filings or elsewhere.
- Yahoo 18.1% insider vs 5.2% Section 16 roster — still unresolved from baseline.
- Cannabis-real-estate cap-rate market — still no
/macrorun in this field. The 14.5% cap and 13–15% required-return build remain reasoned judgments unanchored to observed transactions. The ±100bp fragility flag from the baseline still applies to this pass's NAV number — a Level-of-confidence risk, not a directional one. - Uplisting timeline — "actively evaluating" without a filed application is unfalsifiable. If the Nov print carries the same phrasing, that becomes a fifth-year data point of revealed preference and belongs in a Playbook note on "management describing an available action to justify not doing it."
- DEA ALJ recommendation — pending as of this pass; not a decision, not binding on Administrator Cole.
Single-source conclusions to flag: The HG Vora reduction rests on a single 13G/A filing summary and has not been cross-read against 13F data. Direction is unambiguous; magnitude might refine by ±5% of position on the primary read.
Sources
Primary since baseline: - Q2 2026 press release, Aug 5 2026 - Q2 2026 8-K earnings release - Q2 2026 investor slides — cannabis normalization - Credit-facility extension + Kentucky dispensary press release - HG Vora 13G/A — 650,000 shares / 3.1% - Q3 2026 dividend $0.43, Sep 15 2026
Regulatory: - DEA post-hearing brief — argues for Sched III (Aug 18) - DEA rescheduling milestone Aug 2026 (CannIntel)
Baseline & internal:
- Baseline: Output/Stocks/REITs/NLCP/analyze-2026-08-04.md
- analysis_notes.md §1–§5 · Knowledge/Playbook/pitfall-vendor-feeds-misread-sales-type-lease-reits.md · principle-reit-wacc-has-no-tax-shield.md · pitfall-multiple-trim-inherits-the-broken-vendor-field.md · pitfall-dyt-inverts-when-price-caused-the-yield.md
- Yahoo Finance MCP · .mcp/fin.py NLCP --news